A biotech conducted a phase II study to analyze the percent expression of CD8+ mRCC tumor samples. This secondary endpoint was done by means of IHC simplex method and chromogenic detection through Cerba Research labs.
After garnering CD8+ data, there was a strong scientific interest in retrospectively assessing tumor-infiltrating CD39+ CD8+ in mRCC. Of note, high tumor-infiltrating CD39+ CD8+T cells may indicate poor prognosis in RCC.
Discover how our scientists rose to the challenge and assist the biotech to realize its phase II study.